Skip to main content

Outage notice:

Due to the global information outage that occurred Friday, Quest is taking swift action to respond, recover and restore our operations. Our Patient Services are operating with reduced capacity so you may experience longer wait and service times. Our Customer Contact teams are currently unavailable. We appreciate your patience as we work toward returning to normal operations. 


Diagnostic insights for all stages of lung cancer

Lung cancer is the leading cause of cancer-related deaths in the United States.1 You can trust our testing expertise to help detect and manage lung cancer. We deliver powerfully exceptional diagnosis, prognosis, treatment, and monitoring services for your patients throughout their cancer journey.


The Lung Cancer Mutation Panel (EGFRKRAS and EML4-ALK) will help assess your patients with non-small cell lung cancer (NSCLC) who are being considered for treatment with Tyrosine Kinase Inhibitors, thereby predicting eligibility for NSCLC targeted therapies, while providing targeted information, exceptional customer support and supporting better outcomes.

Treatment selection


The Quest Advanced Oncology LungSEQ Concurrent Panel, part of our comprehensive solution for lung cancer diagnostics, is a disease-targeted NGS panel. We’ve developed these and other decision-support tools to help physicians create a treatment plan for navigating within standard of care and clinical trial options, based on the mutations found in the patient’s tumor.
The LungSEQ Concurrent Panel simultaneously performs NGS and FISH, and includes KRAS G12C, a recently discovered actionable biomarker for some types of lung cancer.

Solid Tumor Core Panel

Quest also offers a 49-gene Solid Tumor Core Panel to help physicians choose the most appropriate therapy for their patients based on the mutations found in the patient’s tumor.

This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.



  1. Ettinger DS, Akerley W, Borghaei H, et al. Practice guideline: non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 2013;11(6):645-653. doi:10.6004/jnccn.2013.0084